Publication | Closed Access
Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
197
Citations
30
References
2020
Year
Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with <i>HER2</i>-mutant NSCLC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1